2-氰基-3-((3-碘苯基)氨基)丙烯酸乙酯 | 364793-63-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氰基-3-((3-碘苯基)氨基)丙烯酸乙酯
• 英文名称: Ethyl 2-cyano-3-(3-iodoanilino)prop-2-enoate
• CAS: 364793-63-5
• 化学式: C₁₂H₁₁IN₂O₂
• 分子量: 342.136
• InChiKey: NFCCTTRPZWOPPX-UHFFFAOYSA-N

物化性质

• 沸点：
  407.8±45.0 °C(Predicted)
• 密度：
  1.678±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氰基-3-((3-碘苯基)氨基)丙烯酸乙酯 在 三氯氧磷 作用下， 生成 4-氯-7-碘-喹啉-3-甲腈
  参考文献：
  名称：

  Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors

  摘要：

  Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial Parkinson's disease (PD). The kinase activity of this complex protein is increased by pathogenic mutations. Inhibition of LRRK2 kinase activity has therefore emerged as a promising approach for the treatment of PD. Herein we report our findings on a series of 4-alkylamino-7-aryl-3-cyanoquinolines that exhibit kinase inhibitory activity against both wild type and G2019S mutant LRRK2. Activity was determined in both biochemical and cellular assays. Compound 14 was further evaluated in an in vivo pharmacodynamic study and found to significantly inhibit Ser935 phosphorylation after oral dosing. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.041
• 作为产物：
  描述：

  3-碘苯胺 、 2-氰基-3-乙氧基丙烯酸乙酯 以 neat (no solvent) 为溶剂， 以98%的产率得到2-氰基-3-((3-碘苯基)氨基)丙烯酸乙酯
  参考文献：
  名称：

  Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors

  摘要：

  Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial Parkinson's disease (PD). The kinase activity of this complex protein is increased by pathogenic mutations. Inhibition of LRRK2 kinase activity has therefore emerged as a promising approach for the treatment of PD. Herein we report our findings on a series of 4-alkylamino-7-aryl-3-cyanoquinolines that exhibit kinase inhibitory activity against both wild type and G2019S mutant LRRK2. Activity was determined in both biochemical and cellular assays. Compound 14 was further evaluated in an in vivo pharmacodynamic study and found to significantly inhibit Ser935 phosphorylation after oral dosing. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.041

文献信息

• Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles
  作者：Diane H. Boschelli、Daniel Y. Wang、Fei Ye、Ayako Yamashita、Nan Zhang、Dennis Powell、Jennifer Weber、Frank Boschelli

  DOI：10.1016/s0960-894x(02)00302-5

  日期：2002.8

  Based on a screening lead from a yeast-based assay to identify Src family kinase inhibitors, a series of 4-anilino-7-thienyl-3-quinolinecarbonitriles was prepared. When the thiophene ring was substituted with a water-solubilizing group in a 2,5-, 3,5- or 2,4-pattern, potent inhibition of Src kinase activity was observed. (C) 2002 Elsevier Science Ltd. All rights reserved.